三神经疼痛中的抗疗法:以类为导向的系统性审查
Miguel Pinto Moreira1, Bruno Daniel Carneiro1,2, Carlos Silva Faria3
1Experimental Biology Unit, Department of Biomedicine, Faculty of Medicine of Porto, University of Porto, 4200-319 Porto, Portugal.
Medicines (Basel, Switzerland)
|February 20, 2026
概括
抗震剂是三角神经疼痛 (TN) 的关键. 通道阻断剂是有效的,但有副作用,而其他选择提供更好的耐受性来管理这种慢性面部疼痛.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 三神经疼痛 (TN) 是一种衰弱的慢性神经病症,导致严重的面部疼痛.
- 抗药是TN的主要药物治疗方法.
- 通过作用机制对抗药疗效和安全性的比较证据有限.
研究的目的:
- 系统地审查和评估TN抗药的疗效和安全性.
- 根据抗药的作用机制对发现进行分层.
主要方法:
- 在PubMed,Scopus和Web of Science (PRISMA 2020指南) 的系统文献搜索.
- 包括使用药理疗法的TN人类患者的研究,自2000年以来以英语出版.
- 使用Cochrane RoB 2,ROBINS-I和ROBINS-E工具进行偏差风险评估.
主要成果:
- 十二项研究符合922个初始记录中的资格标准.
- 通道抑制剂显示高效,但经常出现不良反应 (例如,低血症,中枢神经系统症状).
- 通道调节剂呈现出更好的安全性概况; 莱维他和托皮拉显示出中等的疗效和良好的耐受性. 通道阻塞剂是有效的,但比替代品更难耐受.
结论:
- 对TN的药物选择应考虑作用机制.
- 根据患者个体特征和疼痛表型量身定制治疗对于平衡疗效和耐受性至关重要.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: Sodium Channel Blockers
1.9K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.9K
Antiepileptic Drugs: Calcium Channel Blockers
1.4K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.4K
Electroconvulsive Therapy
1.4K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.4K


